-
Adams J, Kauffman M, 2004: Development of the proteasome inhibitor Velcade (Bortezomib)[J]. Cancer Investig, 22, 304-311. doi: 10.1081/CNV-120030218
-
Altun M, Galardy PJ, Shringarpure R, Hideshima T, LeBlanc R, Anderson KC, Ploegh HL, Kessler BM, 2005: Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells[J]. Cancer Res, 65, 7896-7901. doi: 10.1158/0008-5472.CAN-05-0506
-
Blakqori G, Delhaye S, Habjan M, Blair CD, Sanchez-Vargas I, Olson KE, Attarzadeh-Yazdi G, Fragkoudis R, Kohl A, Kalinke U, Weiss S, Michiels T, Staeheli P, Weber F, 2007: La Crosse bunyavirus nonstructural protein NSs serves to suppress the type Ⅰ interferon system of mammalian hosts[J]. J Virol, 81, 4991-4999. doi: 10.1128/JVI.01933-06
-
Boccadoro M, Morgan G, Cavenagh J, 2005: Preclinical evaluation of the proteasome inhibitor Bortezomib in cancer therapy[J]. Cancer Cell Int, 5, 18-. doi: 10.1186/1475-2867-5-18
-
Chang MS, Woo JH, 2013: Severe fever with thrombocytopenia syndrome: tick-mediated viral disease[J]. J Korean Med Sci, 28, 795-796. doi: 10.3346/jkms.2013.28.6.795
-
Choy MM, Zhang SL, Costa VV, Tan HC, Horrevorts S, Ooi EE, 2015: Proteasome inhibition suppresses dengue virus egress in antibody dependent infection[J]. PLoS Negl Trop Dis, 9, e0004058-. doi: 10.1371/journal.pntd.0004058
-
Davies AM, Lara PN Jr, Mack PC, Gumerlock PH, Bold RJ, Gandara DR, 2005: Bortezomib-based combinations in the treatment of non-small-cell lung cancer[J]. Clin L Cancer, 7, S59-S63. doi: 10.3816/CLC.2005.s.010
-
Dudek SE, Luig C, Pauli EK, Schubert U, Ludwig S, 2010: The clinically approved proteasome inhibitor PS-341 efficiently blocks influenza A virus and vesicular stomatitis virus propagation by establishing an antiviral state[J]. J Virol, 84, 9439-9451. doi: 10.1128/JVI.00533-10
-
Emeny JM, Morgan MJ, 1979: Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production[J]. J Gen Virol, 43, 247-252. doi: 10.1099/0022-1317-43-1-247
-
Gori-Savellini G, Valentini M, Cusi MG, 2013: Toscana virus NSs protein inhibits the induction of type Ⅰ interferon by interacting with RIG-I[J]. J Virol, 87, 6660-6667. doi: 10.1128/JVI.03129-12
-
Keck F, Amaya M, Kehn-Hall K, Roberts B, Bailey C, Narayanan A, 2015: Characterizing the effect of Bortezomib on rift valley fever virus multiplication[J]. Antivir Res, 120, 48-56. doi: 10.1016/j.antiviral.2015.05.004
-
Klinger PP, Schubert U, 2005: The ubiquitin-proteasome system in HIV replication: potential targets for antiretroviral therapy[J]. Expert Rev Anti Infect Ther, 3, 61-79. doi: 10.1586/14787210.3.1.61
-
Lee SM, Yen HL, 2012: Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection[J]. Antivir Res, 96, 391-404. doi: 10.1016/j.antiviral.2012.09.013
-
Lei XY, Liu MM, Yu XJ, 2015: Severe fever with thrombocytopenia syndrome and its pathogen SFTSV[J]. Microbes Infect, 17, 149-154. doi: 10.1016/j.micinf.2014.12.002
-
Li J, Han Y, Xing Y, Li S, Kong L, Zhang Y, Zhang L, Liu N, Wang Q, Wang S, Lu S, Huang Z, 2014: Concurrent measurement of dynamic changes in viral load, serum enzymes, T cell subsets, and cytokines in patients with severe fever with thrombocytopenia syndrome[J]. PLoS One, 9, e91679-. doi: 10.1371/journal.pone.0091679
-
Li X, Liu Y, Wu T, Jin Y, Cheng J, Wan C, Qian W, Xing F, Shi W, 2015: The antiviral effect of baicalin on enterovirus 71 in vitro[J]. Viruses, 7, 4756-4771. doi: 10.3390/v7082841
-
Liu Q, He B, Huang SY, Wei F, Zhu XQ, 2014: Severe fever with thrombocytopenia syndrome, an emerging tick-borne zoonosis[J]. Lancet Infect Dis, 14, 763-772. doi: 10.1016/S1473-3099(14)70718-2
-
Low JG, Sung C, Wijaya L, Wei Y, Rathore APS, Watanabe S, Tan BH, Toh L, Chua LT, Hou Y, Chow A, Howe S, Chan WK, Tan KH, Chung JS, Cherng BP, Lye DC, Tambayah PA, Ng LC, Connolly J, Hibberd ML, Leo YS, Cheung YB, Ooi EE, Vasudevan SG, 2014: Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial[J]. Lancet Infect Dis, 14, 706-715. doi: 10.1016/S1473-3099(14)70730-3
-
Ludwig S, 2009: Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy[J]. J Antimicrob Chemother, 64, 1-4. doi: 10.1093/jac/dkp161
-
Marine JC, Lozano G, 2010: Mdm2-mediated ubiquitylation: p53 and beyond[J]. Cell Death Differ, 17, 93-102. doi: 10.1038/cdd.2009.68
-
Nguyen NM, Tran CN, Phung LK, Duong KT, Huynh HLA, Farrar J, Nguyen QT, Tran HT, Nguyen CV, Merson L, Hoang LT, Hibberd ML, Aw PP, Wilm A, Nagarajan N, Nguyen DT, Pham MP, Nguyen TT, Javanbakht H, Klumpp K, Hammond J, Petric R, Wolbers M, Nguyen CT, Simmons CP, 2013: A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients[J]. J Infect Dis, 207, 1442-1450. doi: 10.1093/infdis/jis470
-
Ning YJ, Wang M, Deng M, Shen S, Liu W, Cao WC, Deng F, Wang YY, Hu Z, Wang H, 2014: Viral suppression of innate immunity via spatial isolation of TBK1/IKKepsilon from mitochondrial antiviral platform[J]. J Mol Cell Biol, 6, 324-337. doi: 10.1093/jmcb/mju015
-
Ning YJ, Feng K, Min YQ, Cao WC, Wang M, Deng F, Hu Z, Wang H, 2015: Disruption of type Ⅰ interferon signaling by the nonstructural protein of severe fever with thrombocytopenia syndrome virus via the hijacking of STAT2 and STAT1 into inclusion bodies[J]. J Virol, 89, 4227-4236. doi: 10.1128/JVI.00154-15
-
Park SW, Song BG, Shin EH, Yun SM, Han MG, Park MY, Park C, Ryou J, 2014: Prevalence of severe fever with thrombocytopenia syndrome virus in Haemaphysalis longicornis ticks in South Korea[J]. Ticks Tick Borne Dis, 5, 975-977. doi: 10.1016/j.ttbdis.2014.07.020
-
Planz O, 2013: Development of cellular signaling pathway inhibitors as new antivirals against influenza[J]. Antivir Res, 98, 457-468. doi: 10.1016/j.antiviral.2013.04.008
-
Qu B, Qi X, Wu X, Liang M, Li C, Cardona CJ, Xu W, Tang F, Li Z, Wu B, Powell K, Wegner M, Li D, Xing Z, 2012: Suppression of the interferon and NF-kappaB responses by severe fever with thrombocytopenia syndrome virus[J]. J Virol, 86, 8388-8401. doi: 10.1128/JVI.00612-12
-
Ruegg UT, Burgess GM, 1989: Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases[J]. Trends Pharmacol Sci, 10, 218-220. doi: 10.1016/0165-6147(89)90263-0
-
Saijo M, 2018: Pathophysiology of severe fever with thrombocytopenia syndrome and development of specific antiviral therapy[J]. J Infect Chemother, 24, 773-781. doi: 10.1016/j.jiac.2018.07.009
-
Santiago FW, Covaleda LM, Sanchez-Aparicio MT, Silvas JA, Diaz-Vizarreta AC, Patel JR, Popov V, Yu XJ, Garcia-Sastre A, Aguilar PV, 2014: Hijacking of RIG-I signaling proteins into virus-induced cytoplasmic structures correlates with the inhibition of type Ⅰ interferon responses[J]. J Virol, 88, 4572-4585. doi: 10.1128/JVI.03021-13
-
Sun Y, Jin C, Zhan F, Wang X, Liang M, Zhang Q, Ding S, Guan X, Huo X, Li C, Qu J, Wang Q, Zhang S, Zhang Y, Wang S, Xu A, Bi Z, Li D, 2012a: Host cytokine storm is associated with disease severity of severe fever with thrombocytopenia syndrome[J]. J Infect Dis, 206, 1085-1094. doi: 10.1093/infdis/jis452
-
Sun Y, Liang M, Qu J, Jin C, Zhang Q, Li J, Jiang X, Wang Q, Lu J, Gu W, Zhang S, Li C, Wang X, Zhan F, Yao W, Bi Z, Wang S, Li D, 2012b: Early diagnosis of novel SFTS bunyavirus infection by quantitative real-time RT-PCR assay[J]. J Clin Virol, 53, 48-53. doi: 10.1016/j.jcv.2011.09.031
-
Tamaoki T, Nomoto H, Takahashi I, Kato Y, Morimoto M, Tomita F, 1986: Staurosporine, a potent inhibitor of phospholipid/Ca++ dependent protein kinase[J]. Biochem Biophys Res Commun, 135, 397-402. doi: 10.1016/0006-291X(86)90008-2
-
Thomas M, Pim D, Banks L, 1999: The role of the E6-p53 interaction in the molecular pathogenesis of HPV[J]. Oncogene, 18, 7690-7700. doi: 10.1038/sj.onc.1202953
-
Tricou V, Minh NN, Van TP, Lee SJ, Farrar J, Wills B, Tran HT, Simmons CP, 2010: A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults[J]. PLoS Negl Trop Dis, 4, e785-. doi: 10.1371/journal.pntd.0000785
-
Wang J, Maldonado MA, 2006: The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases[J]. Cell Mol Immunol, 3, 255-261.
-
Watanabe T, Kawaoka Y, 2015: Influenza virus-host interactomes as a basis for antiviral drug development[J]. Curr Opin Virol, 14, 71-78. doi: 10.1016/j.coviro.2015.08.008
-
Wu X, Qi X, Qu B, Zhang Z, Liang M, Li C, Cardona CJ, Li D, Xing Z, 2014: Evasion of antiviral immunity through sequestering of TBK1/IKKepsilon/IRF3 into viral inclusion bodies[J]. J Virol, 88, 3067-3076. doi: 10.1128/JVI.03510-13
-
Xu B, Liu L, Huang X, Ma H, Zhang Y, Du Y, Wang P, Tang X, Wang H, Kang K, Zhang S, Zhao G, Wu W, Yang Y, Chen H, Mu F, Chen W, 2011: Metagenomic analysis of fever, thrombocytopenia and leukopenia syndrome (FTLS) in Henan Province, China: discovery of a new bunyavirus[J]. PLoS Pathog, 7, e1002369-. doi: 10.1371/journal.ppat.1002369
-
Yu XJ, Liang MF, Zhang SY, Liu Y, Li JD, Sun YL, Zhang L, Zhang QF, Popov VL, Li C, Qu J, Li Q, Zhang YP, Hai R, Wu W, Wang Q, Zhan FX, Wang XJ, Kan B, Wang SW, Wan KL, Jing HQ, Lu JX, Yin WW, Zhou H, Guan XH, Liu JF, Bi ZQ, Liu GH, Ren J, Wang H, Zhao Z, Song JD, He JR, Wan T, Zhang JS, Fu XP, Sun LN, Dong XP, Feng ZJ, Yang WZ, Hong T, Zhang Y, Walker DH, Wang Y, Li DX, 2011: Fever with thrombocytopenia associated with a novel bunyavirus in China[J]. N Engl J Med, 364, 1523-1532. doi: 10.1056/NEJMoa1010095
-
Yuste VJ, Sanchez-Lopez I, Sole C, Moubarak RS, Bayascas JR, Dolcet X, Encinas M, Susin SA, Comella JX, 2005: The contribution of apoptosis-inducing factor, caspase-activated DNase, and inhibitor of caspase-activated DNase to the nuclear phenotype and DNA degradation during apoptosis[J]. J Biol Chem, 280, 35670-35683. doi: 10.1074/jbc.M504015200
-
Zhang YZ, Zhou DJ, Xiong Y, Chen XP, He YW, Sun Q, Yu B, Li J, Dai YA, Tian JH, Qin XC, Jin D, Cui Z, Luo XL, Li W, Lu S, Wang W, Peng JS, Guo WP, Li MH, Li ZJ, Zhang S, Chen C, Wang Y, de Jong MD, Xu J, 2011: Hemorrhagic fever caused by a novel tick-borne bunyavirus in Huaiyangshan, China[J]. Zhonghua Liu Xing Bing Xue Za Zhi, 32, 209-220. doi: 10.1631/jzus.B1000265